Literature DB >> 24780098

Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.

C Arimany-Nardi1, E Errasti-Murugarren, G Minuesa, J Martinez-Picado, V Gorboulev, H Koepsell, M Pastor-Anglada.   

Abstract

BACKGROUND AND
PURPOSE: Inhibitors of DNA methyltransferases (DNMTs), such as azacytidine, decitabine and zebularine, are used for the epigenetic treatment of cancer. Their action may depend upon their translocation across the plasma membrane. The aim of this study was to identify transporter proteins contributing to DNMT inhibitor action. EXPERIMENTAL APPROACH: Drug interactions with selected hCNT and hENT proteins were studied in transiently transfected HeLa and MDCK cells. Interaction with human organic cation transporters (hOCTs) was assessed in transiently transfected HeLa cells and Xenopus laevis oocytes. KEY
RESULTS: Zebularine uptake was mediated by hCNT1, hCNT3 and hENT2. Decitabine interacted with but was not translocated by any nucleoside transporter (NT) type. hCNT expression at the apical domain of MDCK cells promoted net vectorial flux of zebularine. Neither hOCT1 nor hOCT2 transported decitabine, but both were involved in the efflux of zebularine, suggesting these proteins act as efflux transporters. hOCT1 polymorphic variants, known to alter function, decreased zebularine efflux. CONCLUSIONS AND IMPLICATIONS: This study highlights the influence of human NTs and hOCTs on the pharmacokinetics and pharmacodynamics of selected DNMT inhibitors. As hOCTs may also behave as efflux transporters, they could contribute either to chemoresistance or to chemosensitivity, depending upon the nature of the drug or combination of drugs being used in cancer therapy.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24780098      PMCID: PMC4128049          DOI: 10.1111/bph.12748

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

Review 1.  Metformin pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Srijib Goswami; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

2.  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Authors:  M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2009-06-17       Impact factor: 6.875

3.  Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

Authors:  Míriam Molina-Arcas; Beatriz Bellosillo; F Javier Casado; Emili Montserrat; Joan Gil; Dolors Colomer; Marçal Pastor-Anglada
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

4.  Expression of concentrative nucleoside transporters SLC28 (CNT1, CNT2, and CNT3) along the rat nephron: effect of diabetes.

Authors:  Sílvia Rodríguez-Mulero; Ekaitz Errasti-Murugarren; José Ballarín; Antonio Felipe; Alain Doucet; F Javier Casado; Marçal Pastor-Anglada
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

5.  Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.

Authors:  Shivangi Gupta; Gerald Wulf; Maja Henjakovic; Hermann Koepsell; Gerhard Burckhardt; Yohannes Hagos
Journal:  J Pharmacol Exp Ther       Date:  2011-12-27       Impact factor: 4.030

6.  Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.

Authors:  P Arndt; C Volk; V Gorboulev; T Budiman; C Popp; I Ulzheimer-Teuber; A Akhoundova; S Koppatz; E Bamberg; G Nagel; H Koepsell
Journal:  Am J Physiol Renal Physiol       Date:  2001-09

7.  Cloning and characterization of two human polyspecific organic cation transporters.

Authors:  V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell
Journal:  DNA Cell Biol       Date:  1997-07       Impact factor: 3.311

Review 8.  SLC28 genes and concentrative nucleoside transporter (CNT) proteins.

Authors:  M Pastor-Anglada; P Cano-Soldado; E Errasti-Murugarren; F J Casado
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

9.  Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.

Authors:  Rajgopal Govindarajan; Christopher J Endres; Dale Whittington; Edward LeCluyse; Marçal Pastor-Anglada; Chung-Ming Tse; Jashvant D Unadkat
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-07-17       Impact factor: 4.052

Review 10.  DNA methylation profiling in the clinic: applications and challenges.

Authors:  Holger Heyn; Manel Esteller
Journal:  Nat Rev Genet       Date:  2012-09-04       Impact factor: 53.242

View more
  8 in total

1.  Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Authors:  Michal Chovanec; Fadi Taza; Maitri Kalra; Noah Hahn; Kenneth P Nephew; Michael J Spinella; Costantine Albany
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 2.  Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.

Authors:  Syed Saqib Ali; Ruchika Raj; Tejinder Kaur; Brenna Weadick; Debasis Nayak; Minnsung No; Jane Protos; Hannah Odom; Kajal Desai; Avinash K Persaud; Joanne Wang; Rajgopal Govindarajan
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

Review 3.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

4.  Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.

Authors:  Siennah R Miller; Xiaohong Zhang; Raymond K Hau; Joseph L Jilek; Erin Q Jennings; James J Galligan; Daniel H Foil; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington
Journal:  Mol Pharmacol       Date:  2020-12-01       Impact factor: 4.436

Review 5.  Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

6.  Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.

Authors:  Mika Hosokawa; Mai Saito; Aiko Nakano; Sakura Iwashita; Ayano Ishizaka; Kumiko Ueda; Seigo Iwakawa
Journal:  Oncol Lett       Date:  2015-05-22       Impact factor: 2.967

7.  Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.

Authors:  Thomas Briot; Emilie Roger; Nolwenn Lautram; Alexis Verger; Anne Clavreul; Frederic Lagarce
Journal:  Int J Nanomedicine       Date:  2017-11-23

8.  Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia.

Authors:  Yoshiya Adachi; Yuichi Ishikawa; Hitoshi Kiyoi
Journal:  Oncotarget       Date:  2017-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.